Stericycle Inc. (SRCL) Receives $90.64 Consensus Target Price from Analysts
Shares of Stericycle Inc. (NASDAQ:SRCL) have earned an average recommendation of “Hold” from the seventeen research firms that are currently covering the company. Four equities research analysts have rated the stock with a sell recommendation, nine have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $90.64.
A number of brokerages recently weighed in on SRCL. Zacks Investment Research raised Stericycle from a “strong sell” rating to a “hold” rating in a research report on Monday, October 31st. Wedbush reaffirmed a “neutral” rating and set a $85.00 price objective on shares of Stericycle in a research report on Wednesday, November 9th. Jefferies Group reaffirmed a “buy” rating and set a $140.00 price objective on shares of Stericycle in a research report on Monday, July 18th. Wellington Shields downgraded Stericycle from an “accumulate” rating to a “hold” rating in a research report on Friday, July 29th. Finally, Imperial Capital downgraded Stericycle from an “in-line” rating to an “underperform” rating and dropped their price objective for the company from $100.00 to $93.50 in a research report on Friday, July 29th.
Shares of Stericycle (NASDAQ:SRCL) opened at 75.00 on Wednesday. The stock’s 50 day moving average is $76.41 and its 200 day moving average is $90.51. The stock has a market cap of $6.42 billion, a price-to-earnings ratio of 27.26 and a beta of 0.17. Stericycle has a 52-week low of $72.20 and a 52-week high of $128.94.
Stericycle (NASDAQ:SRCL) last issued its quarterly earnings data on Thursday, October 27th. The company reported $1.24 earnings per share for the quarter, beating analysts’ consensus estimates of $1.17 by $0.07. Stericycle had a return on equity of 15.33% and a net margin of 7.52%. The company had revenue of $890.10 million for the quarter, compared to the consensus estimate of $899.87 million. During the same quarter last year, the company earned $1.08 earnings per share. The firm’s revenue for the quarter was up 23.9% compared to the same quarter last year. On average, equities analysts predict that Stericycle will post $4.74 EPS for the current fiscal year.
In related news, Director Rodney F. Dammeyer sold 10,188 shares of Stericycle stock in a transaction that occurred on Wednesday, August 17th. The stock was sold at an average price of $85.50, for a total transaction of $871,074.00. Following the completion of the transaction, the director now directly owns 10,188 shares in the company, valued at $871,074. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP John P. Schetz sold 1,398 shares of Stericycle stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $81.85, for a total value of $114,426.30. Following the transaction, the executive vice president now owns 1,088 shares of the company’s stock, valued at $89,052.80. The disclosure for this sale can be found here. Corporate insiders own 3.30% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Jana Partners LLC bought a new position in shares of Stericycle during the first quarter valued at $305,997,000. Generation Investment Management LLP bought a new position in shares of Stericycle during the second quarter valued at $237,333,000. Baillie Gifford & Co. boosted its position in shares of Stericycle by 77.2% in the second quarter. Baillie Gifford & Co. now owns 2,940,515 shares of the company’s stock valued at $306,166,000 after buying an additional 1,281,519 shares in the last quarter. Swedbank bought a new position in shares of Stericycle during the second quarter valued at $104,155,000. Finally, Fairpointe Capital LLC bought a new position in shares of Stericycle during the second quarter valued at $65,273,000. Institutional investors own 89.05% of the company’s stock.
Stericycle, Inc is a business-to-business services provider with a focus on regulated and compliance solutions for healthcare, retail and commercial businesses. The Company’s solutions include the collection and processing of specialized waste for disposal, the collection of personal and confidential information for secure destruction, and a range of training, consulting, recall/return, communication and compliance services.
Receive News & Stock Ratings for Stericycle Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stericycle Inc. and related stocks with our FREE daily email newsletter.